EN DE
Watch HLB Pharmaceutical Co. Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

HLB Pharmaceutical Co. Ltd (047920) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of HLB Pharmaceutical Co. Ltd stock KRW 1,784, price KRW 7,220, that is 75.3% below the price, quality 40 out of 100. Rating: strongly overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7047920004

HP HLB Pharmaceutical Co. Ltd logo Some data Nov 8, 2026

HLB Pharmaceutical Co. Ltd

047920 · KQ
Very expensive, weak quality

Our calculation puts a fair price 75% below what the stock costs today.

Low debt
Revenue last quarter +33% vs. a year ago.
Quality 40/100
Expensive Growth (revenue 5y +38.3 %/yr in KRW)
Thin margins · 1.1% net margin (TTM)
Some data
Fair value 1,784 KRW · Strongly overvalued
Negative free cash flow
Trails peers (3/12)
Narrow moat 22/100 · thin data
Watch HLB Pharmaceutical Co. Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

41,100 KRW 6,170 KRW Fair Value 1,784 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range 6,170 KRW – 41,100 KRW · fair‑value band 1,338 KRW – 2,230 KRW · the 7,220 KRW price screens above the 1,784 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow HLB Pharmaceutical Co. in your weekly email

Every Wednesday you see whether HLB Pharmaceutical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

HLB Pharmaceutical Co., Ltd. researches and develops peptide drugs in South Korea.

Show moreShow less

The company offers skeletal muscle relaxant, tranquilizers, antihistamines, antihypertensive agents, pain relief, antipruritics, astringents, anti-inflammatories, alimentary system drugs, metabolic drugs, ophthalmic agents, local anesthetics, antiarteriosclerotic agents, expectorants, antipyretics, analgesics, antidiabetic drug, chemotherapeutics, peptic ulcer agents, central nervous system drug, antibiotics, digestives, antacids, dental drugs, multivitamins, parasistic skin disese drugs, dermatlogicals, agents for urogenital organ, amino acid agent, antitussive, mucolytic agents, anthelmintics, antidiarrheals, circulatory system drug, vitamins, skin softeners, anti-hemorrhoid drugs, and agents for liver disease.

It is also developing CTT-004 for the treatment of ataxia induced by spinocerebellar degeneration; and offers CMO services. The company was formerly known as Mediforum Pharmaceutical Incorporation and changed its name to HLB Pharmaceutical Co., Ltd in October 2020.

HLB Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Namyangju-si, South Korea.

Stock analysis

HLB Pharmaceutical Co. Ltd (047920) currently trades at 7,220 KRW, while our model-based Fair Value estimate is 1,784 KRW, 75% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of 4,628 KRW per share, and 1 of the 14 models we run sit above the 7,220 KRW price.

Bear case: the Asset-Based group reads lowest at 715.50 KRW, and 13 of the 14 models stay below the price. Data coverage for this calculation is medium.

Scenario range: 1,338 KRW (bear) to 2,230 KRW (bull), the price of 7,220 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

HLB Pharmaceutical Co. Ltd reported revenue of 206B KRW in FY2025 versus 62.9B KRW in FY2021, a compound +34.5%/yr. Reported net income was 4.6B KRW in FY2025.

Key figures

Market cap 313B KRW (≈ $232M) Micro · P/E ratio 113.8 · P/S ratio 1.24 · EPS (TTM) 63.29 KRW · Net margin 1.1% · Return on equity 2.2% · Return on assets (EBIT) −2.8% (5-year average) · Operating margin −0.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).

What moves the price

The share trades about 65% below its 52-week high and 17% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −75%, 047920 screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely (147.80 KRW to 12,519 KRW). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear 1,338 KRW Fair Value 1,784 KRW Bull 2,230 KRW
Price 7,220 KRW · Downside -75.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (54.28 KRW per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV 362.76 KRW 390.47 KRW 413.96 KRW 74
ROIC Compounder 362.76 KRW 390.47 KRW 413.96 KRW 72
Residual Income 2,014 KRW 1,979 KRW 2,042 KRW 71
All 14 models by family
Earnings-Based
Graham-Dodd 713.66 KRW 4,977 KRW 6,984 KRW 63
Lynch FV 2,410 KRW 3,442 KRW 4,475 KRW 61
PEG = 1.0 2,410 KRW 3,442 KRW 4,475 KRW 57
EPV 362.76 KRW 390.47 KRW 413.96 KRW 74
Multiples
P/E Multiple 1,732 KRW 2,309 KRW 2,886 KRW 63
P/S Multiple 1,338 KRW 1,784 KRW 2,230 KRW 58
P/B Multiple 9,389 KRW 12,519 KRW 15,649 KRW 55
EV/EBIT 141.70 KRW 245.49 KRW 349.28 KRW 64
EV/EBITDA 1,078 KRW 1,494 KRW 1,910 KRW 67
EV/Revenue 52.56 KRW 147.80 KRW 243.04 KRW 50
Asset-Based
NCAV (Graham) 472.23 KRW 715.50 KRW 894.38 KRW 54
Economic Profit
Residual Income 2,014 KRW 1,979 KRW 2,042 KRW 71
ROIC Compounder 362.76 KRW 390.47 KRW 413.96 KRW 72
Growth Earnings
Growth-Adj P/E 3,239 KRW 4,628 KRW 6,016 KRW 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 40/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 54
How much profit the company makes from its sales and capital
Quality Growth 62
Are margins and returns getting better?
Cashflow 5
Do the profits arrive as real cash?
Financial strength 64
Debt, balance sheet and risk of trouble
Investment 65
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 20
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 4
Distance to the 52-week high, does not count
New shares 12
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+50.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+38.3%
Start year 2020 (pandemic). Over 10 years: +27.8% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.3%
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+32.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+32.5%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.32.5% vs 11.1%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−5% → 1%
Pace: the 5-year rate starts in 2020 (pandemic)

047920 screens overvalued: fair value 75% below the price. Compare with Merck KGaA →

Compare HLB Pharmaceutical Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 551 stocks

Beats the industry median on 2/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 40 · Bottom 25%
Fair Value upside −75.3% · Bottom 25%
Profitability
Return on equity (12 months) 2.2% · Below median
Return on assets 2.7% · Below median
Net margin (12 months) 1.1% · Below median
Operating margin (12 months) −0.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 32.7% · Top 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 113.8× · Priciest 25%
P/B 2.50× · Pricier than median
P/S (12 months) 1.24× · Cheaper than median
EV/EBITDA 47.7× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 15
FUTURE (revenue growth)100 · sector 25
PAST (return on equity)9 · sector 29
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $113.53 +43% vs 047920
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥49.23 ¥55.21 +12% vs 047920
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,947 +2% vs 047920
Haleon plc HLN $9.14 $8.61 −6% vs 047920
Merck KGaA MRK €149.20 €109.18 −27% vs 047920
Galderma Group GALD CHF 190.65 CHF 109.86 −42% vs 047920
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs 047920
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs 047920
Sandoz Group SDZ CHF 84.46 CHF 39.70 −53% vs 047920
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs 047920

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

HLB Pharmaceutical Co. Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "HLB Pharmaceutical Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/047920

Frequently asked questions

Is HLB Pharmaceutical Co. Ltd (047920) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 1,784 KRW versus a price of 7,220 KRW, about 75% lower (overvalued).
What is the fair value of 047920?
Our model-based fair value for HLB Pharmaceutical Co. Ltd is 1,784 KRW (as of Nov 8, 2026), built from audited fundamentals. The current price: 7,220 KRW.
What is the quality score of 047920?
HLB Pharmaceutical Co. Ltd has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for HLB Pharmaceutical Co. Ltd (047920)?
Our model-based price target is the fair value of 1,784 KRW (as of Nov 8, 2026) from 14 valuation models. Cautious scenario 1,338 KRW, optimistic scenario 2,230 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the HLB Pharmaceutical Co. Ltd stock forecast for 2026?
Our models put fair value at 1,784 KRW, about 75% lower versus a price of 7,220 KRW (overvalued). Cautious scenario 1,338 KRW, optimistic scenario 2,230 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of HLB Pharmaceutical Co. Ltd (047920)?
HLB Pharmaceutical Co. Ltd reported trailing-twelve-month revenue of about 252B KRW (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of HLB Pharmaceutical Co. Ltd (047920)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For HLB Pharmaceutical Co. Ltd it is 1,784 KRW per share (as of Nov 8, 2026), against a price of 7,220 KRW. It is the blended result of 14 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is HLB Pharmaceutical Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 047920 trades above its calculated fair value: price 7,220 KRW, fair value 1,784 KRW, a gap of about −75% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 047920?
No. The price is what the market pays today (7,220 KRW); the fair value is what the company's own numbers justify (1,784 KRW). For HLB Pharmaceutical Co. Ltd the two are 5,436 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is HLB Pharmaceutical Co. Ltd worth?
The market values HLB Pharmaceutical Co. Ltd at about 313B KRW (market capitalisation, as of Nov 8, 2026). Per share that is 7,220 KRW; our models calculate a fair value of 1,784 KRW per share.
What do the bullish and bearish scenarios say about 047920?
Our models span a range for HLB Pharmaceutical Co. Ltd: cautious scenario 1,338 KRW, base 1,784 KRW, optimistic 2,230 KRW per share (as of Nov 8, 2026, price 7,220 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 047920?
HLB Pharmaceutical Co. Ltd trades at a price-to-earnings ratio of 113.8 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 1,784 KRW is built from several models across several years. Other multiples: P/B 2.5, P/S 1.2, EV/EBITDA 47.7.
How solid is the balance sheet of HLB Pharmaceutical Co. Ltd (047920)?
Balance-sheet figures for HLB Pharmaceutical Co. Ltd (as of Nov 8, 2026): return on equity 2.2%. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is 047920 from its 52-week high?
HLB Pharmaceutical Co. Ltd trades at 7,220 KRW, about 65% below its 52-week high of 20,900 KRW and 17% above the low of 6,170 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 1,784 KRW is for.
Which stocks are comparable to HLB Pharmaceutical Co. Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is HLB Pharmaceutical Co. Ltd stock attractive at the current price?
The data as of Nov 8, 2026: price 7,220 KRW, calculated fair value 1,784 KRW (−75%), Quality Score 40/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 047920 calculated?
We run HLB Pharmaceutical Co. Ltd through 14 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 1,784 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. HLB Pharmaceutical Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of HLB Pharmaceutical Co. Ltd (047920)?
The closing price on Nov 9, 2026 was 7,220 KRW. Our model-based fair value is 1,784 KRW, about 75% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with HLB Pharmaceutical Co. Ltd right now?
The price sits above even our optimistic bull case (2,230 KRW). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts.

Key figures of HLB Pharmaceutical Co. Ltd

How large is the market capitalisation of HLB Pharmaceutical Co. Ltd (047920)?
The market capitalisation of HLB Pharmaceutical Co. Ltd is 313B KRW (≈ $232M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of HLB Pharmaceutical Co. Ltd (047920)?
The price-to-sales ratio of HLB Pharmaceutical Co. Ltd is 1.24 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of HLB Pharmaceutical Co. Ltd (047920)?
Earnings per share at HLB Pharmaceutical Co. Ltd are 63.29 KRW (price ÷ EPS = P/E 113.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of HLB Pharmaceutical Co. Ltd (047920)?
The net margin of HLB Pharmaceutical Co. Ltd is 1.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of HLB Pharmaceutical Co. Ltd (047920)?
The return on equity (ROE) of HLB Pharmaceutical Co. Ltd is 2.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of HLB Pharmaceutical Co. Ltd (047920)?
On an EBIT basis the return on assets of HLB Pharmaceutical Co. Ltd is −2.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of HLB Pharmaceutical Co. Ltd (047920)?
The operating margin of HLB Pharmaceutical Co. Ltd is −0.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at HLB Pharmaceutical Co. Ltd (047920)?
Revenue at HLB Pharmaceutical Co. Ltd is growing +32.7% versus a year earlier (3y avg +24.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at HLB Pharmaceutical Co. Ltd (047920)?
Earnings per share at HLB Pharmaceutical Co. Ltd are growing −55.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does HLB Pharmaceutical Co. Ltd (047920) generate?
The free cash flow of HLB Pharmaceutical Co. Ltd is −6.6B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does HLB Pharmaceutical Co. Ltd (047920) carry?
The net debt of HLB Pharmaceutical Co. Ltd is 7.4B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch HLB Pharmaceutical Co. Ltd in the live analysis

One click puts HLB Pharmaceutical Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.